The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies

Table 2 Correlations and associations between the MBDA score and disease activity measures

Measure	Time point or period for comparison with MBDA score	Number of available samples	r	p value	β (95% CI)¹	p value
DAS28-ESR	BL	46	0.52	< 0.01	0.05 (0.02–0.07)	< 0.01
	6 M	42	0.49	< 0.01	0.06 (0.02–0.09)	0.01
	∆	38	0.60	< 0.01	0.05 (0.01–0.08)	0.02
ESR	BL	44	0.75	< 0.01	1.20 (0.71–1.70)	< 0.01
	6 M	42	0.66	< 0.01	0.81 (0.36–1.26)	< 0.01
	∆	37	0.48	< 0.01	0.57 (−0.03–1.17)	0.06
DAS28-hsCRP²	BL	25	0.51	< 0.01	0.06 (0.02–0.10)	0.01
	6 M	24	0.45	0.03	0.06 (0.02–0.10)	< 0.01
	∆	23	0.48	0.02	0.05 (0.00–0.09)	< 0.05
hsCRP²	BL	25	0.80	< 0.01	1.24 (0.72–1.76)	< 0.01
	6 M	24	0.80	< 0.01	0.75 (0.41–1.10)	< 0.01
	∆	23	0.71	< 0.01	0.90 (0.60–1.21)	< 0.01
CRP	BL	46	0.75	< 0.01	1.07 (0.62–1.52)	< 0.01
	6 M	40	0.76	< 0.01	0.82 (0.58–1.06)	< 0.01
	∆	37	0.59	< 0.01	0.68 (0.18–1.19)	< 0.01
SJC28	BL	48	0.15	0.32	0.10 (−0.06–0.26)	0.22
	6 M	42	0.26	0.10	0.14 (−0.01–0.28)	0.06
	∆	40	0.42	< 0.01	0.12 (−0.04–0.29)	0.14
TJC28	BL	48	0.23	0.12	0.17 (0.02–0.32)	0.03
	6 M	42	0.25	0.11	0.17 (−0.01–0.34)	0.06
	∆	40	0.28	0.08	0.04 (−0.15–0.23)	0.67
VAS-GH	BL	48	0.20	0.18	0.34 (−0.12–0.79)	0.14
	6 M	42	0.27	0.09	0.46 (−0.08–0.99)	0.09
	∆	40	0.36	0.02	0.74 (0.08–1.40)	0.03
HAQ	BL	39	0.02	0.91	0.06 (−0.06–0.02)	0.30
	6 M	41	−0.03	0.85	−0.01 (− 0.01–0.01)	0.84
	∆	34	0.19	0.28	0.00 (−0.01–0.01)	0.77

DAS28 disease activity score using 28 joints, ESR erythrocyte sedimentation rate, hsCRP high-sensitivity C-reactive protein, SJC28 swollen joint count assessing 28 joints, TJC28 tender joint count assessing 28 joints, VAS-GH patient visual analogue scale for general health, HAQ health assessment questionnaire, MBDA multi-biomarker disease activity, BL MBDA score and measure both at baseline, 6 M MBDA score and measure both at month 6, ∆ change in MBDA score and measure, both from baseline to month 6, r Spearman’s rank correlation, CI confidence interval
¹β: regression coefficient from multivariable linear regression analysis, after adjustment by age, gender, smoking status, RF status, ACPA status, and cohort
²HORUS cohort only

ISSN: 1478-6362